Ulotaront

Small moleculeexperimental

Clinical trial activity

28 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
13
Phase 2
12
Phase 3
12
Phase 4
0

Earliest trial started Aug 1, 2013 (NCT01940159)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CNC[C@@H]1OCCc2ccsc21
Mol. weight
183.28 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • sep-363856

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07225712Phase 3Dec 31, 2025Otsuka
NCT06894212Phase 3Feb 28, 2025Otsuka
NCT05848700Phase 1Jun 21, 2023Sumitomo Dainippon
NCT05741528Phase 3Mar 31, 2023Sumitomo Dainippon
NCT05729373Phase 2/Phase 3 (Phase 3)Mar 8, 2023Sumitomo Dainippon
NCT05628103Phase 3Nov 24, 2022Sunovion
NCT05542264Phase 1Nov 15, 2022Sunovion
NCT05593029Phase 2/Phase 3 (Phase 3)Nov 9, 2022Otsuka, Sumitomo, Sumitomo Dainippon
NCT05463770Phase 1Aug 30, 2022Sunovion
NCT05402111Phase 1Jun 13, 2022Sunovion
NCT05359081Phase 3May 16, 2022Sumitomo
NCT04865835Phase 1May 12, 2021Sunovion
NCT04825860Phase 2/Phase 3 (Phase 3)Mar 29, 2021Sumitomo Dainippon
NCT04369391Phase 1May 15, 2020Sunovion
NCT04325737Phase 1Mar 31, 2020Sumitomo Dainippon
NCT04109950Phase 3Nov 19, 2019Sunovion
NCT04115319Phase 3Nov 15, 2019Sunovion
NCT04092686Phase 3Oct 9, 2019Sunovion
NCT04072354Phase 3Sep 30, 2019Sunovion
NCT04038957Phase 1Jul 30, 2019Sunovion
Showing 20 of 28 trials
Page 1 / 2

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SunovionFor profit181832013
Sumitomo DainipponFor profit7622017
OtsukaFor profit3312022
SumitomoFor profit2112022
4 organizations
Page 1 / 1